Abstract CT219: A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox TrialMichael B. Sawyer, Daniel L. Marks, Allison Gardner et al.|Cancer Research|2026Cited by 0